<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="1" ids="50694">Minocycline</z:chebi>, a semi-synthetic <z:chebi fb="9" ids="27902">tetracycline</z:chebi> antibiotic, is an effective neuroprotective agent in animal models of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> when given in high doses intraperitoneally </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to determine if <z:chebi fb="1" ids="50694">minocycline</z:chebi> was effective at reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size in a Temporary Middle Cerebral <z:mp ids='MP_0006134'>Artery Occlusion</z:mp> model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Rats underwent 90 minutes of TMCAO </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO </plain></SENT>
<SENT sid="4" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) brain staining and Neurological Score evaluation </plain></SENT>
<SENT sid="5" pm="."><plain>Pharmacokinetic studies and hemodynamic monitoring were performed on <z:chebi fb="1" ids="50694">minocycline</z:chebi>-treated rats </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="1" ids="50694">Minocycline</z:chebi> at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing <z:mpath ids='MPATH_124'>infarct</z:mpath> size when administered at 4 hours post TMCAO </plain></SENT>
<SENT sid="7" pm="."><plain>At doses of 3 mg/kg, <z:chebi fb="1" ids="50694">minocycline</z:chebi> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 42% while 10 mg/kg reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 56% </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> at a dose of 10 mg/kg significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size at 5 hours by 40% and the 3 mg/kg dose significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 34% </plain></SENT>
<SENT sid="9" pm="."><plain>With a 6 hour time window there was a non-significant trend in <z:mpath ids='MPATH_124'>infarct</z:mpath> reduction </plain></SENT>
<SENT sid="10" pm="."><plain>There was a significant difference in neurological scores favoring <z:chebi fb="1" ids="50694">minocycline</z:chebi> in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="1" ids="50694">Minocycline</z:chebi> did not significantly affect hemodynamic and physiological variables </plain></SENT>
<SENT sid="12" pm="."><plain>A 3 mg/kg IV dose of <z:chebi fb="1" ids="50694">minocycline</z:chebi> resulted in serum levels similar to that achieved in humans after a standard 200 mg dose </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The neuroprotective action of <z:chebi fb="1" ids="50694">minocycline</z:chebi> at clinically suitable dosing regimens and at a therapeutic time window of at least 4-5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>